Guggenheim Cuts Immunome (NASDAQ:IMNM) Price Target to $25.00

Immunome (NASDAQ:IMNM) had its price target decreased by Guggenheim from $35.00 to $25.00 in a research report report published on Thursday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

IMNM has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital started coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.50.

Immunome Stock Performance

NASDAQ IMNM opened at $8.18 on Thursday. The firm’s 50 day moving average price is $9.76 and its two-hundred day moving average price is $11.55. Immunome has a twelve month low of $8.17 and a twelve month high of $26.70. The stock has a market cap of $652.58 million, a price-to-earnings ratio of -1.01 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. On average, research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This represents a 28.87 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunome

Several large investors have recently made changes to their positions in IMNM. Enavate Sciences GP LLC bought a new stake in shares of Immunome in the 4th quarter valued at approximately $36,939,000. JPMorgan Chase & Co. lifted its holdings in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after purchasing an additional 624,045 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Granahan Investment Management LLC acquired a new stake in Immunome in the 4th quarter worth approximately $3,337,000. Finally, Renaissance Technologies LLC lifted its holdings in Immunome by 2,696.5% in the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after purchasing an additional 304,700 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.